NCT03539380

TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease

TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease: Intermediate-Size Patient Population

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: TauRx Therapeutics Ltd · Industry
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide continued access to TRx0237 to individual patients with early and mild-moderate Alzheimer's disease who do not qualify for participation in an ongoing clinical trial. Eligible participants must have previously completed participation in a clinical trial of TRx0237 conducted by TauRx or have previously taken TRx0237 in a compassionate use program, among other criteria. Patients will be considered where a physician can demonstrate clinical benefit for a patient not meeting these criteria; in these cases, TauRx will consider participation of the patient on a case-by-case basis.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	TRx0237	Starting dose of TRx0237 16 mg/day (unless enrolled under earlier version of protocol and are on an established dose), with flexible dosing after 3 months (4-16 mg/day)

Timeline

• First posted: 2018-05-29
• Last updated: 2024-09-27